1042695-87-3

Basic information

• Product Name: (1R,2R,4S)-2-[(5-hexen-1-ylmethylamino)carbonyl]-4-[[7-methoxy-8- methyl- 2-[4-(1-isopropyl)-2-thiazolyl]-4-quinolinyl]oxy]- Cyclopentanecarboxylic acid methyl ester
• Synonyms: (1R,2R,4S)-2-[(5-hexen-1-ylmethylamino)carbonyl]-4-[[7-methoxy-8- methyl- 2-[4-(1-isopropyl)-2-thiazolyl]-4-quinolinyl]oxy]- Cyclopentanecarboxylic acid methyl ester;(1R,2R,4S)-2-[(5-Hexen-1-ylmethylamino)carbonyl]-4-[[7-methoxy-8-methyl-2-[4-(1-methylethyl)-2-thiazolyl]-4-quinolinyl]oxy]cyclopentanecarboxylic acid methyl ester
• CAS NO: 1042695-87-3
• Molecular Formula: C32H41N3O5S
• Molecular Weight: 579.75
• Mol File: 1042695-87-3.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 707.8±70.0 °C(Predicted)
• Appearance: /
• Density: 1.173±0.06 g/cm3(Predicted)
• PKA: 3.19±0.61(Predicted)
• CAS DataBase Reference: (1R,2R,4S)-2-[(5-hexen-1-ylmethylamino)carbonyl]-4-[[7-methoxy-8- methyl- 2-[4-(1-isopropyl)-2-thiazolyl]-4-quinolinyl]oxy]- Cyclopentanecarboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (1R,2R,4S)-2-[(5-hexen-1-ylmethylamino)carbonyl]-4-[[7-methoxy-8- methyl- 2-[4-(1-isopropyl)-2-thiazolyl]-4-quinolinyl]oxy]- Cyclopentanecarboxylic acid methyl ester(1042695-87-3)
• EPA Substance Registry System: (1R,2R,4S)-2-[(5-hexen-1-ylmethylamino)carbonyl]-4-[[7-methoxy-8- methyl- 2-[4-(1-isopropyl)-2-thiazolyl]-4-quinolinyl]oxy]- Cyclopentanecarboxylic acid methyl ester(1042695-87-3)

Safety Data

• Hazardous Substances Data: 1042695-87-3(Hazardous Substances Data)

Usage

General Description

"(1R,2R,4S)-2-[(5-hexen-1-ylmethylamino)carbonyl]-4-[[7-methoxy-8- methyl- 2-[4-(1-isopropyl)-2-thiazolyl]-4-quinolinyl]oxy]- Cyclopentanecarboxylic acid methyl ester" is a chemical compound that features a complex structure with elements including hexenyl, thiazolyl, isopropyl, methoxy, quinolinyl moieties, methyl ester functionality and a cyclopentane carboxylic acid core. The structural aspects of this molecule suggests potential applications in various areas of organic chemistry, medicinal chemistry or pharmaceutical chemistry. However, specifics of its properties, synthesis, or use are not immediately clear from the compound's name alone. The chemical IUPAC name contains stereospecific designations (1R, 2R, 4S) which denotes specific spatial orientations of the groups surrounding the chiral centers in the molecule - vital info for its 3D structure and potentially its bioactivity.

Upstream product

• 1445591-99-0 (1R,2R)-2-(methoxycarbonyl)-4-oxocyclopentanecarboxylic acid 
• 1703-61-3 racemic trans-cyclopentanone-3,4-dicarboxylic acid 
• 1333964-83-2 2-(4-isopropyl-1,3-thiazol-2-yl)-7-methoxy-8-methyl-4(1H)-quinolinone 
• 1193272-59-1 4-chloro-2-isopropylthiazolyl-7-methoxy-8-methylquinoline 
• 6453-07-2 (+/-)-trans-4-oxo-1,2-cyclopentanedicarboxylic acid bis(methyl ester) 
• 55863-02-0 N-methylhex-5-en-1-amine 
• 862259-02-7 trans-(3R,4R)-3,4-bis(methoxycarbonyl)cyclopentanol 
• 35079-19-7 trans-(1R,2R)-1,2-Bis(methoxycarbonyl)-4-oxocyclopentane 
• 1042695-84-0 methyl (1R,2R,4R)-2-[5-hexen-1-yl-(methyl)carbamoyl]-4-hydroxycyclopentanecarboxylate 
• 923289-21-8 8-methyl-2-[4-(1-methylethyl)-1,3-thiazol-2-yl]-7-(methyloxy)-4-quinolinol 
• 1042695-86-2 C₂₅H₂₈N₂O₆S 
• 1333965-01-7 (1R,3R,4R)-3-[5-hexen-1-yl(methyl)-carbamoyl]-4-(methoxycarbonyl)cyclopentyl 4-nitrobenzoate 
• 1333964-98-9 (1R,2R,4R)-2-(methoxycarbonyl)-4-[(4-nitrobenzoyl)oxy]cyclopentanecarboxylic acid 
• 1333964-95-6 benzyl methyl (1R,2R,4S)-4-[(4-nitro-benzoyl)oxy]-1,2-cyclopentanedicarboxylate 

Relevant articles and documents

PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV

Disclosed is a process for the preparation of certain intermediates, e.g. those in the scheme below: which intermediates and processes are useful in the preparation of the macrocyclic HVC inhibitor Simeprevir.

PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV

The present invention relates to the cinchonidine salt useful in the preparation of intermediates for preparing a macrocyclic HCV inhibitor, as well as processes involving this salt.